A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2

Clare Burn, Natalie Ramsey, Scott J. Garforth, Steven C. Almo, William R. Jacobs, Betsy Herold

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Herpes simplex virus (HSV) infections manifest as recurrent oral or genital mucosal lesions, meningoencephalitis, corneal blindness, and perinatal disease. Subunit vaccines have advanced into the clinic without success. None were tested preclinically in male mice. We compared a single-cycle candidate vaccine deleted in HSV-2 glycoprotein D (ΔgD-2) and subunit gD-2 or gD-1 protein vaccines in a male murine skin model. The ΔgD-2 provided complete protection against 10 times the lethal dose of HSV-1 or HSV-2 clinical isolates, and no latent virus was detected, whereas gD-1- and gD-2-adjuvanted proteins provided little or no protection. Protection correlated with Fc receptor activating but not neutralizing antibody titers.

Original languageEnglish (US)
Pages (from-to)754-758
Number of pages5
JournalJournal of Infectious Diseases
Volume217
Issue number5
DOIs
StatePublished - Mar 1 2018

Fingerprint

Human Herpesvirus 2
Human Herpesvirus 1
Glycoproteins
Vaccines
Skin
Subunit Vaccines
Meningoencephalitis
Fc Receptors
Virus Diseases
Simplexvirus
Blindness
Neutralizing Antibodies
Proteins
Viruses
glycoprotein D-herpes simplex virus type 2

Keywords

  • ADCC
  • HSV
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

@article{1bd9fd15bc18498c9ce8c5f829064df7,
title = "A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2",
abstract = "Herpes simplex virus (HSV) infections manifest as recurrent oral or genital mucosal lesions, meningoencephalitis, corneal blindness, and perinatal disease. Subunit vaccines have advanced into the clinic without success. None were tested preclinically in male mice. We compared a single-cycle candidate vaccine deleted in HSV-2 glycoprotein D (ΔgD-2) and subunit gD-2 or gD-1 protein vaccines in a male murine skin model. The ΔgD-2 provided complete protection against 10 times the lethal dose of HSV-1 or HSV-2 clinical isolates, and no latent virus was detected, whereas gD-1- and gD-2-adjuvanted proteins provided little or no protection. Protection correlated with Fc receptor activating but not neutralizing antibody titers.",
keywords = "ADCC, HSV, Vaccine",
author = "Clare Burn and Natalie Ramsey and Garforth, {Scott J.} and Almo, {Steven C.} and Jacobs, {William R.} and Betsy Herold",
year = "2018",
month = "3",
day = "1",
doi = "10.1093/infdis/jix628",
language = "English (US)",
volume = "217",
pages = "754--758",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2

AU - Burn, Clare

AU - Ramsey, Natalie

AU - Garforth, Scott J.

AU - Almo, Steven C.

AU - Jacobs, William R.

AU - Herold, Betsy

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Herpes simplex virus (HSV) infections manifest as recurrent oral or genital mucosal lesions, meningoencephalitis, corneal blindness, and perinatal disease. Subunit vaccines have advanced into the clinic without success. None were tested preclinically in male mice. We compared a single-cycle candidate vaccine deleted in HSV-2 glycoprotein D (ΔgD-2) and subunit gD-2 or gD-1 protein vaccines in a male murine skin model. The ΔgD-2 provided complete protection against 10 times the lethal dose of HSV-1 or HSV-2 clinical isolates, and no latent virus was detected, whereas gD-1- and gD-2-adjuvanted proteins provided little or no protection. Protection correlated with Fc receptor activating but not neutralizing antibody titers.

AB - Herpes simplex virus (HSV) infections manifest as recurrent oral or genital mucosal lesions, meningoencephalitis, corneal blindness, and perinatal disease. Subunit vaccines have advanced into the clinic without success. None were tested preclinically in male mice. We compared a single-cycle candidate vaccine deleted in HSV-2 glycoprotein D (ΔgD-2) and subunit gD-2 or gD-1 protein vaccines in a male murine skin model. The ΔgD-2 provided complete protection against 10 times the lethal dose of HSV-1 or HSV-2 clinical isolates, and no latent virus was detected, whereas gD-1- and gD-2-adjuvanted proteins provided little or no protection. Protection correlated with Fc receptor activating but not neutralizing antibody titers.

KW - ADCC

KW - HSV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85044519138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044519138&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix628

DO - 10.1093/infdis/jix628

M3 - Article

C2 - 29216362

AN - SCOPUS:85044519138

VL - 217

SP - 754

EP - 758

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -